First-generation blood substitutes: What have we learned? Biochemical and physiological perspectives

Expert Opinion on Biological Therapy

Volumn 7, Issue 5, 2007, Pages 665-675

  Alayash, Abdu I ^a   D'Agnillo, Felice ^a   Buehler, Paul W ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Blood substitutes; Free radicals; Hemoglobin; Nitric oxide; Vascular effects

Indexed keywords

BETA GLOBIN; BLOOD SUBSTITUTE; DEFEROXAMINE; DIASPIRIN CROSSLINKED HEMOGLOBIN; HEMOGLOBIN; HYDROGEN PEROXIDE; METHEMOGLOBIN; OXYGLOBIN; RECOMBINANT HEMOGLOBIN; RECOMBINANT HEMOGLOBIN BASED OXYGEN CARRIER; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; APOPTOSIS; CARDIOVASCULAR SYSTEM; CELL CULTURE; CELL CYCLE ARREST; CELL DAMAGE; CHEMICAL MODIFICATION; CYTOTOXICITY; HEMODYNAMICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NITROSATION; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; BLOOD SUBSTITUTES; DRUG DESIGN; ENDOTHELIAL CELLS; HEMOGLOBINS; HUMANS; MOLECULAR STRUCTURE; NITRIC OXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN ENGINEERING; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34248161572     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.5.665     Document Type: Review

References (66)

1. WINSLOW RM: Red cell substitutes. Semin. Hematol. (2007) 44(1):51-59.
2. ALAYASH AI: Oxygen therapeutics: can we tame haemoglobin? Nat. Rev. Drug Discov. (2004) 3(2):152-159.
3. REISS JG: Oxygen carriers ('blood substitutes')-raison d'etre, chemistry, and some physiology. Chem. Rev. (2001) 101(9):2797-2919. • A comprehensive review of the chemistry of various classes of HBOCs.
4. BOYKINS RA, BUEHLER PW, JIA Y, VENABLE R, ALAYASH AI: O-raffinose crosslinked hemoglobin lacks site-specific chemistry in the central cavity: structural and functional consequences of beta93Cys modification. Proteins (2005) 59(4):840-855. •• These papers (4-6) describe useful characterization techniques that were successfully employed to identify the specific sites of chemical modification in various HBOCs.
5. BUEHLER PW, BOYKINS RA, JIA Y, NORRIS S, FREEDBERG DI, ALAYASH AI: Structural and functional characterization of glutaraldehyde-polymerized bovine hemoglobin and its isolated fractions. Anal. Chem. (2005) 77(11):3466-3478. • See annotation to [4].
6. BUEHLER PW, BOYKINS RA, NORRIS S, ALAYASH AI: Chemical characterization of diaspirin cross-linked hemoglobin polymerized with poly(ethylene glycol). Anal. Chem. (2006) 78(13):4634-4641. • See annotation to [4].
7. AMICONI G, ASCOLI F, BARRA D et al.: Selective oxidation of methionine beta(55)D6 at the alpha 1 beta 1 interface in hemoglobin completely destabilizes the T-state. J. Biol. Chem. (1989) 264(30):17745- 17749.
8. VASQUEZ GB, KARAVITIS M, JI X et al.: Cysteines beta93 and beta112 as probes of conformational and functional events at the human hemoglobin subunit interfaces. Biophys. J. (1999) 76(1 Pt 1):88-97.
9. OTON J, BUCCI E, STEINER RF et al.: Molecular dynamics of hemoglobin subunits as seen by fluorescence spectroscopy. J. Biol. Chem. (1981) 256(14):7248-7256.
10. KHAN I, DANTSKER D, SAMUNI U et al.: Beta 93 modified hemoglobin: kinetic and conformational consequences. Biochemistry (2001) 40(25):7581-7592. • This paper provides an example of how differing but specific modification of one amino acid residue (βCys93) can influence T to R state transitioning and ligand binding kinetics of Hb.
11. NAGABABU E, RAMASAMY S, RIFKIND JM, JIA Y, ALAYASH AI: Site-specific cross-linking of human and bovine hemoglobins differentially alters oxygen binding and redox side reactions producing rhombic heme and heme degradation. Biochemistry (2002) 41(23):7407-7415.
12. JIA Y, RAMASAMY S, WOOD F, ALAYASH AI, RIFKIND JM: Cross-linking with O-raffinose lowers oxygen affinity and stabilizes haemoglobin in a non-cooperative T-state conformation. Biochem. J. (2004) 384(Pt 2):367-375.
13. BALDWIN AL, WILEY EB, ALAYASH AI: Differential effects of sodium selenite in reducing tissue damage caused by three hemoglobin-based oxygen carriers. J. Appl. Physiol. (2004) 96(3):893-903.
14. ABASSI Z, KOTOB S, PIERUZZI F et al.: Effects of polymerization on the hypertensive action of diaspirin cross-linked hemoglobin in rats. J. Lab. Clin. Med. (1997) 129(6):603-610. • This paper shows that the vasopressor effect of HBOCs may not depend solely on the presence of tetrameric Hb in HBOC preparations.
15. JIA Y, BUEHLER PW, BOYKINS RA, VENABLE RM, ALAYASH AI: Structural basis of peroxide-mediated changes in human hemoglobin: a novel oxidative pathway. J. Biol. Chem. (2007) 282(7):4894-4907. • This is the first paper to describe the specific amino acid residues of Hb that are attacked by hydrogen peroxide.
16. HUANG L, WOJCIECHOWSKI G, ORTIZ DE MONTELLANO PR: Role of heme-protein covalent bonds in mammalian peroxidases. Protection of the heme by a single engineered heme-protein link in horseradish peroxidase. J. Biol. Chem. (2006) 281(28):18983-18988.
17. OSAWA Y, DARBYSHIRE JF, MEYER CA, ALAYASH AI: Differential susceptibilities of the prosthetic heme of hemoglobin-based red cell substitutes. Implications in the design of safer agents. Biochem. Pharmacol. (1993) 46(12):2299-305.
18. D'AGNILLO F, ALAYASH AI: Oxyhemoglobin and apoptosis. J. Neurosurg. (2000) 92(5):899-902.
19. D'AGNILLO F, ALAYASH AI: Redox cycling of diaspirin cross-linked hemoglobin induces G2/M arrest and apoptosis in cultured endothelial cells. Blood (2001) 98(12):3315-3323. •• This paper identified a specific form of endothelial cell death induced by the ferryl form of HBOCs in vitro.
20. D'AGNILLO F, WOOD F, PORRAS C, MACDONALD VW, ALAYASH AI: Effects of hypoxia and glutathione depletion on hemoglobin- and myoglobin-mediated oxidative stress toward endothelium. Biochim. Biophys. Acta (2000) 1495(2):150-159.
21. MCLEOD LL, ALAYASH AI: Detection of a ferrylhemoglobin intermediate in an endothelial cell model after hypoxia-reoxygenation. Am. J. Physiol. (1999) 277:H92-H99.
22. YEH LH, ALAYASH AI: Effects of cell-free hemoglobin on hypoxia-inducible factor (HIF-1alpha) and heme oxygenase (HO-1) expressions in endothelial cells subjected to hypoxia. Antioxid. Redox Signal. (2004) 6(6):944-953.
23. D'AGNILLO F, ALAYASH AI: Interactions of hemoglobin with hydrogen peroxide alters intracellular thiol levels and the course of endothelial cell death. Am. J. Physiol. Heart Circ. Physiol. (2000) 279(4):H1880- H1889.
24. D'AGNILLO F: Redox active hemoglobin enhances lipopolysaccharide-induced injury to cultured bovine endothelial cells. Am. J. Physiol. Heart Circ. Physiol. (2004) 287(4):H1875-H1882.
25. D'AGNILLO F, ALAYASH AI: A role for the myoglobin redox cycle in the induction of endothelial cell apoptosis. Free Radic. Biol. Med. (2002) 33(8):1153-1164.
26. TOUSSAINT-HACQUARD M, DEVAUX Y, LONGROIS D et al.: Biological response of human aortic endothelial cells exposed to acellular hemoglobin solutions developed as potential blood substitutes. Life Sci. (2003) 72(10):1143-1157.
27. CHENG AM, MOORE EE, JOHNSON JL et al.: Polymerized hemoglobin induces heme oxygenase-1 protein expression and inhibits intercellular adhesion molecule-1 protein expression in human lung microvascular endothelial cells. J. Am. Coll. Surg. (2005) 201(4):579-584.
28. DULL RO, DEWITT BJ, DINAVAHI R et al.: Quantitative assessment of hemoglobin-induced endothelial barrier dysfunction. J. Appl. Physiol. (2004) 97(5):1930-1937.
29. MOTTERLINI R, FORESTI R, VANDEGRIFF K, INTAGLIETTA M, WINSLOW RM: Oxidative-stress response in vascular endothelial cells exposed to acellular hemoglobin solutions. Am. J. Physiol. (1995) 269(2 Pt 2):H648-H655.
30. INTAGLIETTA M, CABRALES P, TSAI AG: Microvascular perspective of oxygen-carrying and -noncarrying blood substitutes. Annu. Rev. Biomed. Eng. (2006) 8:289-321. •• A comprehensive review on the effects of HBOCs on the microvasculture.
31. BUEHLER PW, ALAYASH AI: Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems. Transfusion (2004) 44(10):1516-1528. •• A detailed overview of the preclinical and clinical experience with HBOCs and the troubling disconnect between the two.
32. ALAYASH AI, FRATANTONI JC, BONAVENTURA C, BONAVENTURA J, CASHON RE: Nitric oxide binding to human ferrihemoglobins cross-linked between either alpha or beta subunits. Arch. Biochem. Biophys. (1993) 303(2):332-338.
33. DOHERTY DH, DOYLE MP, CURRY SR et al.: Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat. Biotechnol. (1998) 16(7):672-676. •• This paper demonstrated that using recombinant technology to restructure the heme pocket to reduce NO binding could be one approach to alleviate the vasopressor effect of HBOCs.
34. BURHOP K, GORDON D, ESTEP T: Review of hemoglobin-induced myocardial lesions. Artif. Cells Blood Substit. Immobil. Biotechnol. (2004) 32(3):353-374. • The findings in this paper have had an impact on the design of preclinical studies by researchers in the field.
35. REEDER BJ, SHARPE MA, KAY AD, KERR M, MOORE K, WILSON MT: Toxicity of myoglobin and haemoglobin: oxidative stress in patients with rhabdomyolysis and subarachnoid haemorrhage. Biochem. Soc. Trans. (2002) 30(4):745-748.
36. HOLT S, REEDER B, WILSON M et al.: Increased lipid peroxidation in patients with rhabdomyolysis. Lancet (1999) 353(9160):1241.
37. MOORE KP, HOLT SG, PATEL RP et al.: A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failure. J. Biol. Chem. (1998) 273(48):31731-31737.
38. KUBULUS D, RENSING H, PAXIAN M et al.: Influence of heme-based solutions on stress protein expression and organ failure after hemorrhagic shock. Crit. Care Med. (2005) 33(3):629-637.
39. PRZYBOCKI JM, MCCALDEN TA, COLLIER JM, BILLINGS RE: Hepatic inflammatory responses to alphaalpha-cross-linked hemoglobin infusion in rats. J. Lab. Clin. Med. (1998) 131(5):432-441.
40. D'AGNILLO F, CHANG TM: Absence of hemoprotein-associated free radical events following oxidant challenge of crosslinked hemoglobin-superoxide dismutase-catalase. Free Radic. Biol. Med. (1998) 24(6):906-912.
41. MOTTERLINI R, MACDONALD VW: Cell-free hemoglobin potentiates acetylcholine-induced coronary vasoconstriction in rabbit hearts. J. Appl. Physiol. (1993) 75:2224-2233.
42. CABRALES P, TSAI AG, INTAGLIETTA M: Deferoxamine lowers tissue damage after 80% exchange transfusion with polymerized hemoglobin. Antioxid. Redox Signal. (2007) 9:1-10.
43. 2-activated metmyoglobin and other peroxidizing systems. Free Radic. Res. Commun. (1987) 3(1-5):309-317.
44. FAIVRE B, MENU P, LABRUDE P, GRANDGEORGE M, VIGNERON C: Methemoglobin formation after administration of hemoglobin conjugated to carboxylate dextran in guinea pigs. Attempts to prevent the oxidation of hemoglobin. Artif. Cells Blood Substit. Immobil. Biotechnol. (1994) 22(3):551-558.
45. DUNNE J, CARON A, MENU P et al.: Ascorbate removes key precursors to oxidative damage by cell-free haemoglobin in vitro and in vivo. Biochem. J. (2006) 399(3):513-524.
46. WERNERMAN J, LUO JL, HAMMARQVIST F: Glutathione status in critically-ill patients: possibility of modulation by antioxidants. Proc. Nutr. Soc. (1999) 58(3):677-680.
47. ROBINSON MK, ROUNDS JD, HONG RW, JACOBS DO, WILMORE DW: Glutathione deficiency increases organ dysfunction after hemorrhagic shock. Surgery (1992) 112(2):140-147.
48. PALACE V, KUMAR D, HILL MF, KHAPER N, SINGAL PK: Regional differences in non-enzymatic antioxidants in the heart under control and oxidative sttess conditions. J. Mol. Cell Cardiol. (1999) 31(1):193-202.
49. PRZYBELSKI R, DAILY E, KISICKI J, MATTIA-GOLDBERG C, BOUNDS MJ, COLBURN WA: Phase 1 study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit. Care Med. (1996) 24:1993-2000.
50. SAXENA R, WIJNHOUND AD, CARTON H et al.: Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke (1999) 30:993-996.
51. SLOAN EP, KOENIGSBER M, GENS D et al.: Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA (1999) 282:1857-1864.
52. ALAYASH AI, RYAN BA, FRATANTONI JC: Oxidation reactions of human, opossum (Didelphis virginiana) and spot (Leiostomus xanthurus) hemoglobins: a search for a correlation with some structural-functional properties. Comp. Biochem. Physiol. B (1993) 106(2):427-432.
53. DOU YI, MAILLETT DH, EICH RF, OLSON JS: Myoglobin as a model system for designing heme protein based blood substitutes. Biophys. Chem. (2002) 98(1-2):127-148.
54. ALAYASH AI, RYAN BA, EICH RF, OLSON JS, CASHON RE: Reactions of sperm whale myoglobin with hydrogen peroxide: effects of distal pocket mutations on formation and stability of the ferryl intermediare. J. Biol. Chem. (1999) 274(4):2029-2037.
55. RAAT NJ, DOYLE MP, BURHOP KE, KLEIN J, INCE C: Effects of recombinant-hemoglobin solutions rHb2.0 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock. J. Lab. Clin. Med. (2005) 145(1):21-32.
56. WINSLOW RM: Current status of oxygen carriers ('blood substitutes'): 2006. Vox Sang. (2006) 92(2):102-110.
57. HACKERT ML, RIGGS AF: When size matters. Structure (2006) 14(7):1094-1096.
58. CHIANCONE E, BRENOWITZ M, ASCOLI F, BONVENTURA C, BONVENTURA J: Amphitrite oranta erythrocruorin. I. Structural properties and characterization of subunit interactions. Biochim. Biophys. Acta (1980) 623(1):146-162.
59. HIRSCH RE, JELICKS LA, WITTENBERG BA, KAUL DK, SHEAR HJ, HARRINGTON JP: A first evaluation of natural high molecular weight polymeric Lumbricus terrestris hemoglobin as an oxygen carrier. Artif. Cells Blood Substit. Immobil. Biotechnol. (1997) 25(5):429-444.
60. SCHAER DJ, SCHAER CA, BUEHLER PW et al.: CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptaglobin. Blood (2006) 107(1):373-380. • This is the first paper to describe that CD163 can directly bind HBOCs via a haptoglobin-independent pathway and that the type of chemical modifications on the HBOC influence binding.
61. MCGOWN EL, LYONS MF, MARINI MA, ZEGNA A: Reduction of extracellular methemoglobin by erythrocytes. Biochim. Biophys. Acta (1990) 1036:202-206.
62. SU D, MAY JM, KOURY MJ, ASARD H: Human erythrocyte membranes contain a cytochrome B561 that may be involved in extracellular ascorbate recycling. J. Biol. Chem. (2006) 281(52):39852-39859.
63. BALDWIN AL, WILEY EB, SUMMERS AG, ALAYASH AI: Sodium selenite reduces hemoglobin-induced venular leakage in the rat mesentery. Am. J. Physiol. (2003) 284(1):H88-H91.
64. D'AGNILLO F, CHANG TMS: Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties. Nat. Biotechnol. (1998) 16(7):667-671.
65. BUEHLER PW, HANEY CR, GULATI A, MA L, HSIA CJ: Polynitroxyl hemoglobin: a pharmacokinetic study of covalently bound nitroxides to hemoglobin platforms. Free Radic. Biol. Med. (2004) 37(1):124-135.
66. SIMONI J, SIMONI G, WESSON DE, GRISWOLD JA, FEOLA M: A novel hemoglobin-adenosine-glutathione based blood substitute: evaluation of its effects on human blood ex vivo. ASAIO (2000) 46(6):679-692.